Long‐term and multiple hospital readmissions after discharge for Stevens–Johnson syndrome and toxic epidermal necrolysis
暂无分享,去创建一个
[1] B. Kaffenberger,et al. Predictors of 30-day Readmission in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Retrospective, Cross-sectional Database Study. , 2020, Journal of the American Academy of Dermatology.
[2] R. Hui,et al. Anticancer Drugs Induced Severe Adverse Cutaneous Drug Reactions: An Updated Review on the Risks Associated with Anticancer Targeted Therapy or Immunotherapies , 2018, Journal of immunology research.
[3] B. Kaffenberger,et al. Association of Dermatology Consultations With Patient Care Outcomes in Hospitalized Patients With Inflammatory Skin Diseases , 2017, JAMA dermatology.
[4] M. Testa,et al. Nationwide Survey of Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis in Children in the United States , 2017, Pediatric dermatology.
[5] J. Silverberg,et al. Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. , 2016, The Journal of investigative dermatology.
[6] D. Margolis,et al. Identification of Stevens–Johnson syndrome and toxic epidermal necrolysis in electronic health record databases , 2015, Pharmacoepidemiology and drug safety.